FDA Approves Triple Therapy Polypill for High Blood Pressure
The combination will be available in several doses and is also approved as a first-line option for patients with hypertension.
Related Articles
MitraClip Safe and Effective in Non-COAPT-Like Patients: EXPANDed
The data indicate it’s worth a shot to try TEER in many with secondary MR, but clinical judgement is critical.
Roughly Half of Patients Don’t Have Symptoms Prior to a First MI
The findings from a contemporary US cohort point to the need for better ways to identify and treat those who are at risk.
Early-Bird Registration Is Open | Complications 2025
JULY 10-12 2025 | GRAND HYATT SEATTLE | SEATTLE, WA Sponsored by the Cardiovascular Research Foundation ®, this three-day comprehensive course examines not only procedural…
The Hidden Demands of Cardiology Training
Perhaps it’s time to rethink how much personal sacrifice is necessary in the name of learning to become a physician.
The STEEER-AF Trial
Dipak Kotecha talks to C. Michael Gibson about whether educating healthcare providers on rhythm-control therapy affects guideline adherence and stroke outcomes.
No Benefit of Sentinel Device During TAVI: Updated Meta-analysis
Some believe that future studies are still needed to tease out whether there are high-risk subgroups who will benefit.
Catheter Ablation for AF: Fewer Strokes, Deaths, and HF Hospitalizations
The benefit seems durable, but one expert says patients should be aware there’s “some risk of stroke” during the procedure.
CMS Agrees to Reimburse Tricuspid TEER
The overall evidence for the procedure is “insufficient” at present, but good enough to allow coverage, the agency says.
Early-Bird Registration Is Open | Complications 2025
JULY 10-12 2025 | GRAND HYATT SEATTLE | SEATTLE, WA Sponsored by the Cardiovascular Research Foundation ®, this three-day comprehensive course examines not only procedural…
Good Outcomes, Little Hospital Experience: Pascal TEER in Real World
The study led to questions about whether patients would be best served by being treated at high-volume centers of excellence.